Gabapentin and pregabalin, calcium channel alpha-2-delta ligands, can modulate neuronal hyperexcitability and reduce sensory processing abnormalities associated with Visual Snow Syndrome by dampening glutamatergic neurotransmission. These medications potentially improve sleep architecture and neurological symptom intensity through their ability to stabilize neuronal membranes and reduce aberrant cortical signaling, thereby mitigating the perceptual disturbances characteristic of the syndrome.